AIM ImmunoTech Valuation

Is 0A4Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A4Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A4Y's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A4Y's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A4Y?

Other financial metrics that can be useful for relative valuation.

0A4Y key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue45.4x
Enterprise Value/EBITDA-0.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does 0A4Y's PB Ratio compare to its peers?

The above table shows the PB ratio for 0A4Y vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4x
PBX ProBiotix Health
8.3xn/aUK£10.7m
SNG Synairgen
1x50.2%UK£9.2m
HEMO Hemogenyx Pharmaceuticals
5.7xn/aUK£17.4m
VRCI Verici Dx
1.1xn/aUK£8.2m
0A4Y AIM ImmunoTech
2.6x6.5%US$15.8m

Price-To-Book vs Peers: 0A4Y is good value based on its Price-To-Book Ratio (2.6x) compared to the peer average (4x).


Price to Earnings Ratio vs Industry

How does 0A4Y's PE Ratio compare vs other companies in the GB Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a37.8%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a37.8%
n/an/an/a
No more companies

Price-To-Book vs Industry: 0A4Y is good value based on its Price-To-Book Ratio (2.6x) compared to the UK Biotechs industry average (3.1x).


Price to Book Ratio vs Fair Ratio

What is 0A4Y's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A4Y PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0A4Y's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A4Y forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.26
US$3.17
+1,137.0%
52.1%US$5.00US$1.00n/a3
Oct ’25US$0.28
US$3.50
+1,163.1%
35.0%US$5.00US$2.00n/a3
Sep ’25US$0.39
US$3.50
+809.1%
35.0%US$5.00US$2.00n/a3
Aug ’25US$0.36
US$3.58
+895.4%
37.1%US$5.25US$2.00n/a3
Jul ’25US$0.40
US$3.58
+798.2%
37.1%US$5.25US$2.00n/a3
Jun ’25n/a
US$3.58
0%
37.1%US$5.25US$2.00n/a3
May ’25n/a
US$3.50
0%
35.0%US$5.00US$2.00n/a3
Apr ’25US$0.48
US$2.75
+468.8%
27.3%US$3.50US$2.00n/a2
Mar ’25US$0.41
US$3.83
+826.4%
43.0%US$6.00US$2.00n/a3
Feb ’25US$0.42
US$3.83
+813.1%
43.0%US$6.00US$2.00n/a3
Jan ’25US$0.44
US$3.83
+779.2%
43.0%US$6.00US$2.00n/a3
Dec ’24US$0.48
US$3.83
+706.8%
43.0%US$6.00US$2.00n/a3
Nov ’24US$0.43
US$3.83
+791.3%
43.0%US$6.00US$2.00US$0.263
Oct ’24US$0.53
US$3.83
+626.3%
43.0%US$6.00US$2.00US$0.283
Sep ’24US$0.64
US$3.92
+511.0%
44.9%US$6.25US$2.00US$0.393
Aug ’24US$0.61
US$3.92
+542.1%
44.9%US$6.25US$2.00US$0.363
Jul ’24US$0.63
US$3.92
+521.8%
44.9%US$6.25US$2.00US$0.403
Jun ’24US$0.48
US$3.92
+721.1%
44.9%US$6.25US$2.00n/a3
May ’24US$0.49
US$5.33
+979.6%
30.9%US$6.50US$3.00n/a3
Apr ’24US$0.40
US$5.42
+1,254.2%
31.6%US$6.75US$3.00US$0.483
Mar ’24US$0.51
US$5.42
+962.1%
31.6%US$6.75US$3.00US$0.413
Feb ’24n/a
US$5.42
0%
31.6%US$6.75US$3.00US$0.423
Jan ’24n/a
US$5.42
0%
31.6%US$6.75US$3.00US$0.443
Dec ’23n/a
US$5.42
0%
31.6%US$6.75US$3.00US$0.483
Nov ’23n/a
US$5.58
0%
33.2%US$7.25US$3.00US$0.433

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies